Investigated for growth hormone signaling research.
Third-party verified for identity and purity.
Intended for laboratory research use only, NOT FOR HUMAN USE.
CJC-1295 No DAC + Ipamorelin
Reports
Product
Strength
Components
Appearance
Purity
Use
Storage
Specifications
CJC-1295 w/o DAC+
Ipamorelin
5 mg + 5 mg
CJC-1295 (no DAC) +
Ipamorelin
White Lyophilized Peptide
>99%
Research Use Only
Refrigerate 36 - 46F (2 - 8C) after reconstitution
Precision Growth Hormone Blend
A research peptide combination designed to stimulate endogenous growth hormone release through synergistic GHRH and ghrelin receptor pathways. Studied for recovery, lean body composition, sleep quality, and performance-related research.
Mechanism of Action
CJC-1295
GHRH analog
Stimulates natural GH release
Pulsatile activity
(No Dac)
Ipamorelin
Selective ghrelin receptor agonist
Promotes GH secretion
Minimal effect on cortisol/prolactin
Synergy
Dual-pathway GH stimulation
Supports recovery research
Enhances sleep and body composition research
Research Overview
CJC-1295 (No DAC) combined with Ipamorelin is a synergistic peptide blend studied for its ability to stimulate the body’s natural growth hormone (GH) production through complementary signaling pathways. CJC-1295 (No DAC), a growth hormone-releasing hormone (GHRH) analog, promotes physiologic GH pulsatility, while Ipamorelin, a selective ghrelin receptor agonist, enhances GH release with minimal reported activity on cortisol and prolactin secretion.
Together, this combination has been investigated in preclinical and clinical research for its potential applications in lean body composition, exercise recovery, sleep quality, tissue repair, and healthy aging. The complementary mechanisms of these peptides make them a common subject of research focused on optimizing endogenous growth hormone release while maintaining physiologic hormone patterns.
For laboratory research use only. Not intended for human or veterinary use.